TY - JOUR
T1 - Safety and Outcomes of Test Doses for the Evaluation of Adverse Drug Reactions
T2 - A 5-Year Retrospective Review
AU - Iammatteo, Melissa
AU - Blumenthal, Kimberly G.
AU - Saff, Rebecca
AU - Long, Aidan A.
AU - Banerji, Aleena
N1 - Publisher Copyright:
© 2014.
PY - 2014
Y1 - 2014
N2 - Background: Graded challenges are the criterion standard for evaluating adverse drug reactions (ADR). Evidence-based guidelines regarding the optimal number of steps for challenges are lacking. Objective: To determine the safety and outcomes of 1- or 2-step test doses among patients with ADRs seen by the allergy/immunology consult service and to compare the outcomes of 1- or 2-step test doses with multistep challenges performed during the same time period. Methods: We conducted a retrospective chart review of all 1- or 2-step test doses and multistep challenges at a single academic center between 2008 and 2013. Patient demographics, symptoms of initial ADRs, and outcomes of test doses and multistep challenges were reviewed. ADRs were classified by type and were graded by severity. Outcomes of 1- or 2-step test doses were compared with multistep challenges. Results: We identified 456 patients who underwent 497 one- or 2-step test doses (mean age, 51 years; 67.5% female patients). The most common drugs that prompted test doses were β-lactams (62%). The majority of patients (n= 444 [89%]) did not experience any ADRs during test doses. ADRs that occurred during test doses (n= 53 [11%]) were most commonly non-immune-mediated (45%) or IgE-mediated (32%), with grade 1 or 2 severity (100%). Forty-nine percent of ADRs during test doses did not receive any treatment. The ADR rate during multistep challenges (10/82 [12%]) was similar to test doses. Conclusion: One- or 2-step test doses were safe for evaluation of ADRs. Multistep challenges did not confer added safety. Furthermore, 1- or 2-step test doses did not raise concern for induction of tolerance.
AB - Background: Graded challenges are the criterion standard for evaluating adverse drug reactions (ADR). Evidence-based guidelines regarding the optimal number of steps for challenges are lacking. Objective: To determine the safety and outcomes of 1- or 2-step test doses among patients with ADRs seen by the allergy/immunology consult service and to compare the outcomes of 1- or 2-step test doses with multistep challenges performed during the same time period. Methods: We conducted a retrospective chart review of all 1- or 2-step test doses and multistep challenges at a single academic center between 2008 and 2013. Patient demographics, symptoms of initial ADRs, and outcomes of test doses and multistep challenges were reviewed. ADRs were classified by type and were graded by severity. Outcomes of 1- or 2-step test doses were compared with multistep challenges. Results: We identified 456 patients who underwent 497 one- or 2-step test doses (mean age, 51 years; 67.5% female patients). The most common drugs that prompted test doses were β-lactams (62%). The majority of patients (n= 444 [89%]) did not experience any ADRs during test doses. ADRs that occurred during test doses (n= 53 [11%]) were most commonly non-immune-mediated (45%) or IgE-mediated (32%), with grade 1 or 2 severity (100%). Forty-nine percent of ADRs during test doses did not receive any treatment. The ADR rate during multistep challenges (10/82 [12%]) was similar to test doses. Conclusion: One- or 2-step test doses were safe for evaluation of ADRs. Multistep challenges did not confer added safety. Furthermore, 1- or 2-step test doses did not raise concern for induction of tolerance.
KW - Adverse drug reaction
KW - Drug allergy
KW - Drug provocation test
KW - Graded challenge
KW - Hypersensitivity reaction
KW - Test dose
UR - http://www.scopus.com/inward/record.url?scp=84922377976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922377976&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2014.08.001
DO - 10.1016/j.jaip.2014.08.001
M3 - Article
C2 - 25439369
AN - SCOPUS:84922377976
SN - 2213-2198
VL - 2
SP - 768
EP - 774
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 6
ER -